Xceleron sign an agreement with Biofrontera Bioscience GmbH to accelerate drug development using microdosing
19-Jul-2006 -
Xceleron, a service provider specialising in zeptoanalysis to accelerate drug development, announce an agreement for a Phase 0 microdose study with Biofrontera Bioscience GmbH, a member of the German Biofrontera Group, specializing in the development of drugs for the treatment of dermatological ...
clinical trials
drug development
inflammation
+4